 
 
Approval Date :  
 05-Dec-2018 
Protocol 1883-301-013       
AGN-190584 
 1 
Title Page 
Protocol Title: A Phase 3, Multicenter, Do uble-Masked, Randomized, Vehicle-Controlled, 
Parallel-Group Study Evaluating the Safety and Efficacy of AGN-190584 in Participants 
with Presby[CONTACT_608176]: 1883-301-013 
Amendment Number: [ADDRESS_843356]: AGN-190584  
Brief Protocol Title: Phase 3 efficacy study of AGN-190584 in participants with presby[CONTACT_631907]: 3 
Sponsor Name: [CONTACT_78562], Inc.  
Legal Registered Address:  
[ADDRESS_843357], Irvine, CA [ZIP_CODE], [LOCATION_003]  
Serious Adverse Event Reporting:   
Allergan Medical Safety Physician Contact [CONTACT_7171]:  
Allergan Signatory:   
Vice President, Therapeutic Area Head 
Anterior Segment and Consumer Eye Care Allergan, Inc. 
Refer to the final page of this protocol fo r electronic signature [CONTACT_51472]. 

 
 
Approval Date :  
 05-Dec-2018 
Protocol 1883-301-013       
AGN-190584 
 2 
Protocol Amendment Summary of Changes 
DOCUMENT HISTORY 
Document Date 
Amendment 1 05 December 2018 
Original Protocol 13 October 2018 
Amendment 1 (05 December 2018) 
Overall Rationale for the Amendment: 
The following is a summary of changes made to the original protocol, some of which are based 
on communication with the FDA. 
Section No. and 
Name [CONTACT_631931], tables, appendices, and text to a 30-day study intervention timeline A 30-day study intervention period is an adequate duration to demonstrate safety and efficacy of 
AGN-190584 
1.1. Synopsis; 1.3. Schedule of Activities; 3. 
Objectives and 
Endpoints; 8. Study 
Assessments and 
Procedures; 10.7. Appendix 7 Add OD and OS measurements for mesopic and photopic CDVA, DCIVA, and DCNVA In addition to binocular measurements, individual 
eye measurements were added to mesopic and 
photopic CDVA, DCIVA, and DCNVA to provide a more complete assessment of these 
endpoints 
1.1. Synopsis; 4.1. 
Overall Design; 
9.2. Sample Size 
Determination Modify participant dropout rate to 10% and participants completing the study 
per study intervention group to 
approximately 135 The participant dropout rate assumption was modified to 10% (versus 20%) as this is a sufficiently conservative estimate of participants 
who may not complete the 30-day study. 
Assumptions for the sample size calculation and their basis were clarified.  
1.1. Synopsis; 6.3. Measures to 
Minimize Bias: 
Randomization and Blinding; 
[IP_ADDRESS]. 
Secondary Analyses; [IP_ADDRESS]. 
Subgroup 
Analyses Modify “baseline DCNVA” to “baseline binocular DCNVA” for 
randomization and analysis “Baseline DCNVA” was modified to “baseline 
binocular DCNVA” to clarify this stratification 
parameter during randomization and statistical 
analysis 
1.3. Schedule of 
Activities; 8.8. 
Biomarkers and Other Add determination of dominant eye Collection of participant dominant/nondominant eye data was clarified 

 
 
Approval Date :  
 05-Dec-2018 
Protocol 1883-301-013       
AGN-190584 
 3 
Section No. and 
Name [CONTACT_631932]; 
10.7. Appendix 7 
1.3. Schedule of 
Activities; 10.7.1. 
Screening Visit 
(Days -30 to -1) Modify screening DCNVA assessment 
that will be repeated 3 times with 
different charts to OD only OD was added to clarify that the screening visit 
DCNVA (to be repeated 3 times with different 
charts) is for OD only 
7.1. 
Discontinuation 
of Study 
Intervention Added a guideline to encourage participants who discontinue the study 
intervention early to stay in the study 
for the safety assessments at Day [ADDRESS_843358] was 
updated based on previous phase 2 study results; the intervention effect for the non-emmetropes 
group was added. The total number of 
participants to complete the study was changed to 135 for each treatment group 
9.4.1. Efficacy 
Analyses Remove key secondary efficacy 
endpoint (change from baseline letters AUC
0-[ADDRESS_843359], 
binocular DCNVA at Day 30) and its analysis method This key secondary e fficacy endpoint is not 
required to demonstrate the efficacy of AGN-
190584 
[IP_ADDRESS]. Analysis 
Endpoints Remove secondary efficacy endpoint 
(photopic, high contrast, binocular 
DCIVA mean change from baseline letters AUC
0-10 at Day 30) and its 
analysis method This secondary efficacy en dpoint is not required 
to demonstrate the efficacy of AGN-190584 
[IP_ADDRESS]. Analysis Endpoints Add secondary efficacy endpoint 
(Change from baseline photopic, high 
contrast, binocular DCIVA letters at Day 30, Hour 3) This secondary efficacy endpoint was added to 
evaluate the efficacy of AGN-190584 for DCIVA 
[IP_ADDRESS]. Secondary 
Analyses Update change from baseline analysis 
(MMRM) The change from baseline analysis model (MMRM) was updated to include the following additional fixed effects: visit, visit by [CONTACT_631908], and baseline value 
by [CONTACT_23259] 
[IP_ADDRESS] Subgroup 
Analyses Update subgroup analyses Subgroup analyses by [CONTACT_631909], therefore have not been summarized 
 

 
 
Approval Date :  
 05-Dec-[ADDRESS_843360] of Figures ............................................................................................................... ..................7  
1.  Protocol Summary ..........................................................................................................8  
1.1.  Synopsis ...................................................................................................................... ......8 
1.2.  Schema ........................................................................................................................ ....10 
1.3.  Schedule of Activities .....................................................................................................11  
2.  Introduction .................................................................................................................. .18 
2.1.  Study Rationale ............................................................................................................... 18 
2.2.  Background .................................................................................................................... .18 
2.3.  Benefit/Risk Assessment ................................................................................................19  
3.  Objectives and Endpoints ............................................................................................20  
4.  Study Design .................................................................................................................. 21 
4.1.  Overall Design ................................................................................................................ 21 
4.1.1. Clinical Hypotheses ........................................................................................................21  
4.2.  Scientific Rationale for Study Design ............................................................................21  
4.3.  Justification for Dose ......................................................................................................21  
4.4.  End of Study Definition ..................................................................................................21  
5.  Study Population ...........................................................................................................23  
5.1.  Inclusion Criteria ............................................................................................................ 23 
5.2.  Exclusion Criteria ...........................................................................................................2 4 
5.3.  Lifestyle Considerations .................................................................................................26  
5.4.  Screen Failures ............................................................................................................... .26 
6.  Study Intervention ........................................................................................................27  
6.1.  Study Intervention(s) Administered ................................................................................27  
6.1.1. Study Supplies ................................................................................................................ 27 
6.1.2. Instructions for Use and Administration .........................................................................28  
6.2.  Preparation/Handling/Storage/Accountability ................................................................28  
6.3.  Measures to Minimize Bias: Randomization and Blinding ............................................29  
6.4.  Study Intervention Compliance ......................................................................................30  
6.5.  Concomitant Therapy .....................................................................................................30  
6.5.1. Prohibited Interventions and Washout Before the Study ................................................30  
6.5.2. Permitted Interventions ...................................................................................................31  
6.5.3. Rescue Medicine .............................................................................................................31  
6.5.4. Prohibited Interventions During the Study .....................................................................31  

 
 
Approval Date :  
 05-Dec-2018 
Protocol 1883-301-013       
AGN-190584 
 5 
6.6.  Dose Modification ..........................................................................................................31  
6.7.  Intervention after th e End of the Study ...........................................................................31  
7.  Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal........................................................................................32  
7.1.  Discontinuation of Study Intervention ............................................................................32  
7.2.  Participant Discontinuation/W ithdrawal from the Study ................................................[ADDRESS_843361] Sensitivity ................................................................................................38  
8.2.5. Study Intervention Tolerability a nd Drop Comfort Assessments ...................................38  
8.2.6. Temporal/Supraorbital Headach e Visual Analog Scale .................................................[ADDRESS_843362] Refraction ........................................................................................................42  
8.2.10. Dilated Funduscopic Examination ..................................................................................42  
8.2.11. Suicidal Risk Monitoring ................................................................................................43  
8.3.  Adverse Events and Serious Adverse Events .................................................................43  
8.3.1. Time Period and Frequency for Collecting Adverse Event and 
Serious Adverse Event Information ................................................................................43  
8.3.2. Method of Detecting Adverse Events and Serious Adverse 
Events ........................................................................................................................ ......44 
8.3.3. Follow-up of Adverse Events and Serious Adverse Events ...........................................44  
8.3.4. Regulatory Reporting Requirements fo r Serious Adverse Events ..................................44  
8.3.5. Pregnancy ..................................................................................................................... ...45 
8.3.6. Medication Errors ...........................................................................................................45  
8.4.  Treatment of Overdose ...................................................................................................45  
8.5.  Pharmacokinetics ............................................................................................................46  
8.5.1. Blood Pharmacokinetic Sampling Procedure .................................................................46  
8.5.2. Pharmacokinetic Sample Bioanalysis .............................................................................47  
8.6.  Pharmacodynamics .........................................................................................................47  
8.7.  Genetics ..........................................................................................................................47  
8.8.  Biomarkers and Other Assessments ...............................................................................47  
8.8.1. Biomarkers .................................................................................................................... ..47 
8.8.2. Determination of Dominant Eye .....................................................................................47  
8.9.  Health Economics ...........................................................................................................48  
9.  Statistical Considerations .............................................................................................48  

 
 
Approval Date :  
 05-Dec-2018 
Protocol 1883-301-013       
AGN-190584 
 6 
9.1.  Statistical Hypotheses .....................................................................................................48  
9.2.  Sample Size Determination ............................................................................................49  
9.3.  Populations for Analyses ................................................................................................49  
9.4.  Statistical Analyses .........................................................................................................4 9 
9.4.1. Efficacy Analyses ...........................................................................................................49  
9.4.2. Safety Analyses ...............................................................................................................51  
9.4.3. Pharmacokinetic Analyses ..............................................................................................52  
9.4.4. Other Analyses ................................................................................................................ 52 
9.5.  Interim Analyses .............................................................................................................53  
9.5.1. Data Monitoring Committee ...........................................................................................53  
10.  Supporting Documentation and Operational Considerations ..................................54  
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight 
Considerations ................................................................................................................ 55 
10.1.1. Regulatory and Ethical Considerations ...........................................................................55  
10.1.2. Financial Disclosure ........................................................................................................55  
10.1.3. Informed Consent Process ..............................................................................................56  
10.1.4. Data Protection................................................................................................................ 56 
10.1.5. Posting Clinical Study Data ............................................................................................56  
10.1.6. Data Quality Assurance ..................................................................................................57  
10.1.7. Source Documents ..........................................................................................................57  
10.1.8. Study and Site Closure ....................................................................................................57  
10.1.9. Publication Policy ...........................................................................................................5 8 
10.1.10. Compliance with Protocol...............................................................................................58  
10.2. Appendix 2: Adverse Events: Definitions and Procedures for Recording, Evaluating, Follow-up, and Reporting .........................................................59
 
Definition of AE ............................................................................................................................59  
Definition of SAE ............................................................................................................. .............60  
Recording and Follow-Up of AEs and/or SAEs ............................................................................61  
Reporting of SAEs ............................................................................................................. ............63  
10.3. Appendix 3: Abbreviations .............................................................................................64  
10.4. Appendix 4: Standard Discontinuation Criteria..............................................................66  
10.5. Appendix 5: Study Tabular Summary ............................................................................68  
10.6. Appendix 6: Contraceptive Guidance and Collection of Pregnancy Information ...................................................................................................70
 
Definitions: .................................................................................................................. ..................70  
Contraception Guidance: ....................................................................................................... ........70 
Pregnancy Testing: ............................................................................................................ .............72  
Collection of Pregnancy Information: .......................................................................................... .72 

 
 
Approval Date :  
 05-Dec-2018 
Protocol 1883-301-013       
AGN-190584 
 7 
10.8. Appendix 8: Patient Reported Outcomes Questionnaires, 
Descriptions, and Instructions.........................................................................................[ADDRESS_843363] of Tables 
Table 1-1   Schedule of Visits and Procedur es: Screening to Visit 3 .................................. 11 
Table 1–2   Schedule of Visits and Procedures: Visit 4 to Visit 5/Early Exit ...................... 15 
Table 8-1   Efficacy Assessments ........................................................................................ 35 
Table 10–[ADDRESS_843364] of Figures 
Figure 1-1   Study Schema .................................................................................................... 10  
 

 
 
Approval Date :  
 05-Dec-2018 
Protocol 1883-301-013       
AGN-190584 
 8 
1. Protocol Summary 
1.1. Synopsis 
Protocol Title: A Phase 3, Multicenter, Double-Masked, Randomized, Vehicle-Controlled, 
Parallel-Group Study Evaluating the Safety and Efficacy of AGN-190584 in Participants with 
Presby[CONTACT_608176]:  1883-301-013 
Brief Title:  Phase 3 efficacy study of AGN-190584 in participants with presby[CONTACT_631910]:  
In previous studies, Allergan established the safety and efficacy of several (0.5% to 1.5%) 
concentrations of AGN-190584 dosed once daily, b ilaterally or in the non dominant eye, over a 
period of up to 28 days in participants with presby[CONTACT_19555]. Study 1883-301- 013 is a multicenter, 
double-masked, randomized, vehicle-controlled, pa rallel group, Phase 3 study evaluating the 
efficacy, safety, and pharmacokinetics of AGN-190584 (1.25% pi[INVESTIGATOR_1227]) dosed once daily, 
bilaterally, over a period of 30 days in participants with presby[CONTACT_19555]. 
Objectives and Measures: 
The objectives of this study are to evaluate the efficacy, safety, and pharmacokinetics of AGN-
190584 when administered bilaterally, once daily fo r 30 days in participants with presby[CONTACT_19555]. 

 
 
Approval Date :  
 05-Dec-2018 
Protocol 1883-301-013       
AGN-190584 
 9 
Objectives Measures 
To evaluate the efficacy of AGN-190584 
when administered bilaterally, once daily for 
30 days in participants with presby[CONTACT_19555]. • Mesopic and photopic, high contrast distance-corrected 
near visual acuity (DCNVA) for each eye and binocularly 
• Mesopic and photopic, high contrast distance-corrected 
intermediate visual acuity for each eye and binocularly 
• Patient reported outcomes questionnaires:  
o Mesopic and Photopic Near Vision Presby[CONTACT_143611]-
based Questionnaire 
o Presby[CONTACT_143612][INVESTIGATOR_631879]-190584 when administered bilaterally, 
once daily for 30 days in participants with 
presby[CONTACT_19555] • Adverse events 
• Photopic and mesopic high contrast corrected distance 
visual acuity for each eye and binocularly 
• Near Contrast sensitivity 
• Vital signs (blood pressure and heart rate) 
• Study drug tolerability and drop comfort assessments 
• Temporal/supraorbital headache visual analog scale 
• Intraocular pressure 
• Slit-lamp biomicroscopy 
• Manifest refraction 
• Dilated funduscopic examination 
• Pregnancy test for women of childbearing potential 
To evaluate the pharmacokinetics of 
AGN-190584 when administered bilaterally, 
once daily for 30 days in participants with 
presby[CONTACT_19555] • Plasma concentrations of AGN-190584 (sampled at 
selected sites; approximately 10% of all enrolled 
participants) 
Overall Study Design: 
This is a multicenter, double-masked, randomized , parallel-group, vehicle-controlled, Phase [ADDRESS_843365] of adult male and female 
participants with objective and s ubjective evidence of presby[CONTACT_19555].  
Number of Participants: Approximately [ADDRESS_843366] 135 participants per 
group completing the study based on an assume d dropout rate of 10%. Participants who 
prematurely discontinue from the study will not be replaced. 

 
 
Approval Date :  
 05-Dec-2018 
AGN-19
 Numbe r
There w i
Interve n
Particip a
once dai l
years an d
worse th a
study co n
14, and 3
Data M o
1.2. 
The stud y
Figure 1
 
0584 
r of Sites: 
ill be appro x
ntion Grou p
ants will be r
ly, in each e y
d > 50 years )
an 20/60), i r
nsists of the 
30. 
onitorin g Co
Schem a
y schema is 
-1 Stud y
ximately 50 s
ps and Stud y
randomized i
ye, for 30 d a
), baseline b
ris color (br o
following v
ommittee: N
a 
provided in 
y Schema 
sites in the U
y Duration:
in a 1:1 rati o
ays. This ra n
inocular D C
own and no n
visits: screen i
No 
Figure 1-1.
10 
United State s
 
o to receive e
ndomization 
CNVA (2 gr o
n-brown), an d
ing (Days - 3
s. 
either AGN -
will be stra t
oups: 20/40 t
d emmetrop
30 to -1), D a
Proto c
-190584 or v
tified by [CONTACT_322270] e
to 20/60 inc l
es/non-em m
ay 1 (baseli ncol 1883-30 1
vehicle dose d
e (2 groups: ≤
lusively, an d
metropes. Th i
ne), and Day1-013       
d 
≤ 50 
d 
is 
s 3, 7, 

 
 
 
Approval  Date:  
 05-Dec-2018 
 Protocol 1883-301-013       
AGN-190584 
11 
1.3. Schedule of Activities 

 
 
 
Approval  Date:  
 05-Dec-2018 
 Protocol 1883-301-013       
AGN-190584 
12 

 
 
 
Approval  Date:  
 05-Dec-2018 
 Protocol 1883-301-013       
AGN-190584 

 
 
 
Approval  Date:  
 05-Dec-2018 
 Protocol 1883-301-013       
AGN-190584 
14 

 
 
 
 
Approval  Date:  
 05-Dec-2018 
 Protocol 1883-301-013       
AGN-190584 
15 
Table 1–2 Schedule of Visits and Proce dures: Visit 4 to Visit 5/Early Exit 

 
 
 
 
Approval  Date:  
 05-Dec-2018 
 Protocol 1883-301-013       
AGN-190584 
16 

 
 
 
Approval  Date:  
 05-Dec-2018 
 Protocol 1883-301-013       
AGN-190584 
17 

 
 
Approval Date :  
 05-Dec-2018 
 Protocol 1883-301-013       
AGN-190584 
18 
2. Introduction 
Allergan is investigating pi[INVESTIGATOR_631880] l ophthalmic solution 1.25% (AGN-190584) as a 
noninvasive, reversible, pharmacological treatment for presby[CONTACT_19555], a condition in which the eye 
exhibits a diminished ability to focu s on near objects with increasing age. 
2.1. Study Rationale 
In previous studies, Allergan established the sa fety and efficacy of various concentrations of 
AGN-[ADDRESS_843367] presby[CONTACT_19555], a nd prevalence is expected to increase to 1.782 
billion by 2050 ( Holden 2008). Both nonsurgical and surgical  methods for the correction of 
presby[CONTACT_631911]. Traditional nonsurgical methods of refractive correction for presby[CONTACT_631912], bifocal or varifocal spectacles, and monovision or multifocal contact [CONTACT_13276]. A number of surgical techniques are also used for the treatment of 
presby[CONTACT_19555], which include monovision PRK or LA SIK, conductive kerat oplasty, intraocular 
lenses, and corneal inlays. However, for each of the existing technologies mentioned above, 
visual quality is reduced at 1 or more viewi ng distances, and each comes with its own unique 
safety risks and associated complications. For ex ample, bifocals and progressive lenses (eg, 
reading glasses, contacts) produce optical abe rrations and can increase the risk of falls 
(Johnson 2007, Lord 2002 ). Multifocal optics re duce image quality uniformly at all viewing 
distances. For surgical technologies, surgical risks, and the need for repo sitioning and 
explantation, or regression of effect have limited their widespread adoption ( Moshirfar 2017 , 
Ruiz 2009, Tomita 2015 ). Thus, there remains a need for a noninvasive, reversible, 
pharmacological treatment for presby[CONTACT_19555]. 
Pi[INVESTIGATOR_245460] a muscarinic re ceptor agonist that mimics the actions of the parasympathetic 
neurotransmitter, acetylcholine, on smooth muscle . This causes 2 effects that enhance near 
vision: 1) constriction of the iris sphincter musc le, resulting in pupil constriction (miosis), and 
2) contraction of the ciliary muscle, resulting in centra l lens steepeni ng and lens accommodation 
(focusing from distance to near) (García-Lázaro 2012 ). Reducing the pupil size has long been 
recognized as an effective way to increase the useful depth of focus, in part by [CONTACT_631913] ( Tucker 1975 ). 
Pi[INVESTIGATOR_631881] e currently used for the reduction of elevated IOP in patients 
with open-angle glaucoma or ocular hypertension, management of acute-angle closure glaucoma, 

 
 
Approval Date :  
 05-Dec-2018 
 Protocol 1883-301-013       
AGN-190584 
19 
prevention of postoperative elevated IOP associated with laser surgery, and induction of miosis 
(Pi[INVESTIGATOR_631882] 2011 ). Currently, the us e of pi[INVESTIGATOR_631883] e xperienced AE of temporal and periorbital 
headache (ie, brow ache), which is believed to be  due to the rapi[INVESTIGATOR_631884] ( Tsai 2009). However, Allergan has establis hed an acceptable safety profile of 
AGN-190584 in 3 Phase 2 clinical studie s (Studies 199201-007, 199201-009, and 199201-010). 
This is likely because the posology of pi[INVESTIGATOR_631885] (0.5% to 1.5%) and less frequently administered (once to twice 
daily) than for the treatment of glaucoma (1.0% to  4.0% administered up to 4 times daily). As a 
result, discontinuation rates for all Phase [ADDRESS_843368] improved compared with vehicl e under mesopic and photopic conditions at the 
1.0% and 1.5% pi[INVESTIGATOR_1227] c oncentrations, respectively. 
More detailed information regarding clinical safety  findings, clinical efficacy findings, chemistry, 
and pharmacology is provided in the IB. 
2.3. Benefit/Risk Assessment 
Currently available approaches to presby[CONTACT_143609] (spectacles 
or contact [CONTACT_13276]) and surgical options (PRK or LASIK, conductive kera toplasty, intraocular 
lenses, or corneal inlays). Each approach has its own risk-benefit ratio. Because the risk-benefit 
ratio with nonsurgical options is generally lower than that of surg ical procedures, both historical 
and contemporary practice has been  to attempt nonsurgical or pharmacological treatment before 
resorting to more i nvasive alternatives. 
Although the use of spectacles an d contact [CONTACT_631914], this 
approach has limitations. Multifocal spectacles impair depth perception and edge-contrast sensitivity at critical distances for de tecting obstacles in the environment ( Lord 2002) , and 
varifocal lenses have a corridor of nondistorted vision. For these r easons, older people are more 
than twice as likely to fall when wearing multifocal spectacles, and many participants have difficulty adjusting to using them ( Johnson 2007, Lord 2002). As a result, Allergan is developi[INVESTIGATOR_007] 
a noninvasive, reversible, pharmacol ogical treatment for presby[CONTACT_19555]. 
More detailed information about the known and expected benefits and risks and reasonably 
expected AEs of AGN-190584 may be found in the IB. 

 
 
Approval Date :  
 05-Dec-2018 
 Protocol 1883-301-013       
AGN-190584 
20 
3. Objectives and Endpoints 
Objectives Measures 
To evaluate the efficacy of AGN-190584 
when administered bilaterally, once daily for 
30 days in participants with presby[CONTACT_19555]. • Mesopic and photopic, high contrast DCNVA for each eye 
and binocularly 
• Mesopic and photopic, high contrast DCIVA for each eye 
and binocularly 
• PRO questionnaires:  
o Mesopic and Photopic NVPTQ 
o PI[INVESTIGATOR_631886]-190584 when administered bilaterally, 
once daily for 30 days in participants with 
presby[CONTACT_19555] • AEs 
• Photopic and mesopic high contrast CDVA for each eye 
and binocularly 
• Near Contrast sensitivity 
• Vital signs (blood pressure and heart rate) 
• Study drug tolerability and drop comfort assessments 
• Temporal/supraorbital headache VAS 
• IOP 
• Slit-lamp biomicroscopy 
• Manifest refraction 
• Dilated funduscopic examination 
• Pregnancy test for WOCBP 
To evaluate the pharmacokinetics of 
AGN-190584 when administered bilaterally, 
once daily for 30 days in participants with 
presby[CONTACT_19555] • Plasma concentrations of AGN-190584 (sampled at 
selected sites; approximately 10% of all enrolled 
participants) 
 

 
 
Approval Date :  
 05-Dec-2018 
 Protocol 1883-301-013       
AGN-190584 
21 
4. Study Design 
4.1. Overall Design 
This is a multicenter, double-masked, randomized , parallel-group, vehicle-controlled, Phase 3 
study in participants with presby[CONTACT_19555]. Partic ipants will receive AGN-190584 or vehicle dosed 
once daily, bilaterally, for 30 days. Approxima tely 300 participants with presby[CONTACT_631915] 50 sites in the [LOCATION_002]. 
This study consists of the following visits: screeni ng, Day 1 (baseline), and Days 3, 7, 14, and 30.  
A study schema is located in Section 1.[ADDRESS_843369] 135 participants per 
group completing the study. Participants who prematurely discontinue from the study will not be 
replaced. 
4.1.1.  Clinical Hypotheses 
• AGN-190584 ophthalmic solution dosed bilaterally, once daily for 30 days will 
demonstrate a significant improve ment in DCNV A over vehicle. 
• AGN-190584 ophthalmic solution dosed bilaterally, once daily for 30 days will demonstrate an acceptable safety and tolerability profile. 
4.2. Scientific Rationale for Study Design 
The current Phase 3 clinical study is designed to evaluate the efficacy, safe ty, and tolerability of 
AGN-190584 versus vehicle over a 30-day study intervention period when administered once 
daily bilaterally in par ticipants with presby[CONTACT_19555]. 
Allergan Phase 2 Studies 199201-007 and 199201-009 support the administration of 
AGN-190584 monotherapy as an effective and safe treatment for presby[CONTACT_631916] 1.5%. 
The current Phase 3 study will evaluate AGN-190584 in an expanded participant population to 
establish efficacy and safety. 
4.3. Justification for Dose 
Through modeling and evaluation of the Phase 2 results (Studies 199201-007, 199201-009, and 199201-010), Allergan has determined the optim al dose of AGN-190584 to be 1.25% for the 
treatment of presby[CONTACT_19555]. 
4.4. End of Study Definition 
The EOS is defined as the date of the last visit of the last participant in the study. 

 
 
Approval Date :  
 05-Dec-[ADDRESS_843370] completed th e study if he/she has comp leted all phases of the 
study including the last visit. 

 
 
Approval Date :  
 05-Dec-[ADDRESS_843371] of  adult male and female part icipants with objective and 
subjective evidence of presby[CONTACT_19555]. 
Prospective approval of protocol deviations to recruitment and en rollment criteria, also known as 
protocol waivers or exemptions, is not permitted. 
5.1. Inclusion Criteria 
Participants are eligible to be included in the study only if all of the following criteria apply: 
1. Age 
1.[ADDRESS_843372] activities of daily living,
3. Sex 

 
 
Approval Date :  
 05-Dec-[ADDRESS_843373] icable (eg, Written Authorization for Use 
and Release of Health and Research Study Information for the [LOCATION_002]) 
5. Other  
5.01 Able, as assessed by [CONTACT_093], and willing to follow study instructions and 
likely to complete all required study visits  
 
5.2. Exclusion Criteria 
Participants are excluded from the study if  any of the following criteria apply: 
1. Medical Conditions 
1.[ADDRESS_843374] medications 
2. Prior/Concomitant Therapy 

 
 
Approval Date :  
 05-Dec-2018 
 Protocol 1883-301-013       
AGN-190584 
25 
2.01 Concurrent use of any topi[INVESTIGATOR_20718], including artificial tears, other 
than the study intervention during the course of the study  
2.02 Concurrent use of temporary or permanent punctal plugs or history of  punctal cautery in 
one or both eyes 
3. Prior/Concurrent Clinical Study Experience 
3.01 Current enrollment in an investigational drug or device study or part icipation in such a 
study within 30 days of entry into this study 
3.02 Participation in a blood or plasma donation program within 30 days prior to study intervention administration 
4. Diagnostic Assessments 
4.02 Severe dry eye disease (defined as total corneal staining ≥ grade [ADDRESS_843375] 
scale and an OSDI score of > 33) at the screening visit 
4.03 Corneal abnormalities (including keratoc onus, corneal scar, Fuchs’ endothelial 
dystrophy, guttata, or edema) in either eye that are likely to  interfere with visual acuity 
4.04 Narrow iridocorneal angles (Shaffer grade ≤ 2 or lower on gonioscopy examination), 
history of angle-closure glau coma, or previous iridotomy 
4.05 History of iris trauma, Adie’s tonic pupil, abnormal pupi l shape in either eye, or 
anisocoria > [ADDRESS_843376] lenses for habitual correction. Participants willing to wear study-provided monofocal correction (either spectacles or contact [CONTACT_13276]) during the study can be enrolled 
4.09 Abnormal and clinically significant results acco rding to the investigator or designee, on 
physical/ophthalmic examination or medical history 

 
 
Approval Date :  
 05-Dec-2018 
 Protocol 1883-301-013       
AGN-190584 
26 
5. Other 
5.01 Females who are pregnant, nursing, or planning a pregnancy dur ing the study.
 
5.4. Screen Failures 
Screen failures are defined as participants who c onsent to participate in the clinical study but are 
not subsequently entered in the study. A minimal set of screen failure information is required to 
ensure transparent reporting of screen failure par ticipants to meet the Consolidated Standards of 
Reporting Trials publishing requirements and to re spond to queries from regulatory authorities. 
Minimal information includes demography, screen failure details, eligibil ity criteria, and any 
SAE. 
Individuals who do not meet the cr iteria for participation in this  study (screen failures) may not 
be rescreened. 

 
 
Approval Date :  
 05-Dec-2018 
 Protocol 1883-301-013       
AGN-190584 
27 
6. Study Intervention 
Study intervention is defined as a ny investigational inte rvention intended to be administered to a 
study participant according to the study protocol. 
6.1. Study Intervention(s) Administered 
Study Intervention Name  [CONTACT_143657]-190584 Vehicle 
Dosage Formulation Topi[INVESTIGATOR_631887] 1.25% Ophthalmic 
Solution Pi[INVESTIGATOR_631888] 1.25% Not applicable 
Route of Administration  Topi[INVESTIGATOR_631889]  1 drop in each eye once daily 1 drop in each eye once daily 
Manufacturer Allergan Sales, LLC. Allergan Sales, LLC. 
Number and Timing of 
Interventions 1 drop bilaterally, once daily 1 drop bilaterally, once daily 
 
As this is a double-masked study, AGN-190584 and Vehicle will be supplied in identically 
appearing bottles and cartons. 

 
 
Approval Date :  
 05-Dec-2018 
 Protocol 1883-301-013       
AGN-190584 
28 
6.2. Preparation/Handling/Storage/Accountability 
The investigator or designee must confirm a ppropriate temperature conditions have been 
maintained during transit for all study interventi on received and any discrepancies are reported 
and resolved before use of the study intervention. 

 
 
Approval Date :  
 05-Dec-[ADDRESS_843377] be stored in a 
secure, environmentally controlled, and monito red (manual or automated) area in accordance 
with the labeled storage conditions with access lim ited to the investigator and authorized site 
staff. All study intervention must be stored upright, in a refrigerator, and protected from freezing. 
Participants will be instructed on the proper storag e of study intervention and to keep it out of the 
reach of children at all times. 
6.3. Measures to Minimize Bias: Randomization and Blinding 
All participants will be centrally assigned to randomized study intervention using the IxRS. 
Randomization and kit assignment will be conducted on Day 1 (baseline). At Day 1, participants 
will be randomized in a 1:1 ra tio into 1 of the 2 study groups. This randomization will be 
stratified by [CONTACT_654] (2 groups: ≤ 50 years and > 50 years), baseli ne binocular DCNVA (2 groups: 
20/40 to 20/60 inclusively, and worse than 20/ 60), iris color (brown and non-brown), and 
emmetropes/non-emmetropes. A maximum of 50% (75 per arm) of the participants enrolled will 
have brown iris color, and a maximum of 25% (38 per arm) of the participants will be non-
emmetropes (a sphere outside of -0.50 D to +0 .75 D and/or a cylinder greater than 0.75 D). 

 
 
Approval Date :  
 05-Dec-2018 
 Protocol 1883-301-013       
AGN-190584 
30 
6.5. Concomitant Therapy 
The use of any concomitant medication, prescripti on or over-the-counter, is to be recorded on the 
participant’s eCRF at each visit along with the reason the me dication is taken. 
From screening to the EOS, site staff will question each participant specifically on the use of 
concomitant medications. Site staff must notif y the sponsor immediately if a participant 
consumes any concomitant medications not perm itted by [CONTACT_760]. Participants who used 
prohibited concomitant medications may be discon tinued from the study at the discretion of the 
investigator or the sponsor. 
6.5.1.  Prohibited Interventions and Washout Before the Study 
Use of medications that may have a substantial e ffect on visual function or the optical properties 
of the eye is prohibited 2 weeks prior to Day 1 visit and during the study: 
• systemic medications with potential ocular side effect s, including topi[INVESTIGATOR_052], 
hydroxychloroquine, ethambutol, phosphodiesterase 5 inhibitors (sildenafil, vardenafil, 
tadalafil), or tamoxifen  
• ophthalmic, systemic, or intranasal anticholinergics and α-adrenergic receptor agonists 
with potential pupi[INVESTIGATOR_631890], including oxymetazoline, pi[INVESTIGATOR_1227], 
tetrahydrozoline, phenylephrine, naphazoline, cy clopentolate, atropi[INVESTIGATOR_050], beta-blockers, or 
antihistamines  
• systemic maprotiline, tricyclic antidepre ssants, or monoamine oxidase inhibitors 

 
 
Approval Date :  
 05-Dec-2018 
 Protocol 1883-301-013       
AGN-190584 
31 
6.5.2.  Permitted Interventions 
Any medication or vaccine (including over-the-c ounter or prescription medicines, vitamins, 
and/or herbal supplements) that th e participant is receiving at the time of enrollment or receives 
during the study must be  recorded along with: 
• Indication 
• Dates of administration incl uding start and end dates 
• Dosage information including dose and frequency 
Therapy considered necessary for the participant’ s welfare may be given at the discretion of the 
investigator. If the permissibility of a specifi c medication/intervention is in question, please 
contact [CONTACT_456]. 
The sponsor or designee should be contact[CONTACT_397038] e any questions regarding concomitant or 
prior therapy. 
The concurrent use of nonocular medications that  do not have a substantial effect on the pupil, 
accommodative properties, or retinal function of the eye will be permitted during the study if a 
stable dosing regimen is established. The dosing regimen is not considered to be stable if a 
participant starts, stops, or cha nges the dose/drug during the study. 
Any medication taken during the study between th e date of the first dos e of study intervention 
and the date of the EOS visit will be recorded in the eCRF as a concomitant medication; any 
medication started after the EOS visit will not be considered a concomitant medication and 
should not be captured in the eCRF. 
6.5.3.  Rescue Medicine 
Rescue medicine is not applicable. 
6.5.4.  Prohibited Interventions During the Study 
Use of ocular medications other than study inte rvention or medications administered to conduct 
study procedures are prohibited from the screening visit until study exit. 
The decision to administer a prohibited medication/treatment will be made with the safety of the 
study participant as the primary consideration. Wh en possible, Allergan should be notified before 
the prohibited medication/treatment is administered. 
6.6. Dose Modification 
Dose modification is not applicable. 
6.7. Intervention after the End of the Study 
No interventions after the e nd of the study are planned. 

 
 
Approval Date :  
 05-Dec-2018 
 Protocol 1883-301-013       
AGN-190584 
32 
7. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal 
A premature discontinuation will occur if a par ticipant who signs the ICF and is dosed ceases 
participation in the study, regardless of circum stances, before the completion of the protocol-
defined study procedures. 
Reasons for discontinuation from the study in tervention and/or the study may include the 
following: 
• AE 
• Lack of efficacy 
• Lost to follow-up 
• Noncompliance with study drug 
• Physician decision 
• Pregnancy 
• Protocol deviation 
• Site terminated by [CONTACT_3211] 
• Study terminated by [CONTACT_3211] 
• Withdrawal by [CONTACT_1130] 
• Death  
• Other 
7.1. Discontinuation of Study Intervention 
See the SoA (Section 1.3) for data to be collected at the time of early exit. 
Participants who discontinue the study intervention early will be encouraged to stay in the study 
for the safety assessments at Day 30. 
7.2. Participant Discontinuation/Withdrawal from the Study 
• A participant may withdraw from the study at any time at his/her own request or may be 
withdrawn at any time at the discretion of  the investigator for safety, behavioral, 
compliance, or administrative reasons. 

 
 
Approval Date :  
 05-Dec-2018 
 Protocol 1883-301-013       
AGN-190584 
33 
• If the participant withdraws consent for disclo sure of future information, the sponsor may 
retain and continue to use a ny data collected before such  a withdrawal of consent. 
• If a participant withdraws from the study, he /she may request destruction of any samples 
taken and not tested, and the investigator must document this in the site study records. 
• See the SoA (Section 1.3) for data to be collected at the time of early exit. 
7.3. Lost to Follow Up 
A participant will be considered lost to follow-up if he or she repeatedly fails to return for 
scheduled visits and is unable to be contact[CONTACT_9298]. 
The following actions must be taken if a participant fails to return to the clinic for a required 
study visit: 
• The site must attempt to contact [CONTACT_600028]/or should continue in the 
study. 
• Before a participant is deemed lost to follow-up, the investigator or designee must make every effort to regain contact [CONTACT_6635] (where possi ble, 3 telephone calls and, if 
necessary, a certified letter to the participant’s last known maili ng address or local equivalent 
methods). These contact [CONTACT_600029]’s medical record. 
• Should the participant continue to be unreach able, he/she will be considered to have 
withdrawn from the study. 

 
 
Approval Date :  
 05-Dec-2018 
 Protocol 1883-301-013       
AGN-190584 
34 
8. Study Assessments and Procedures 
• Study procedures and their timing ar e summarized in the SoA (Section 1.3). Protocol 
waivers or exemptions are not allowed. 
• Immediate safety concerns should be discussed with the sponsor promptly upon 
occurrence or awareness to determine if the participant should cont inue or discontinue 
study intervention. 
• Adherence to the study design requirements, including those specified in the SoA, is 
essential and required for study conduct. 
• All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility criteria. The investigator will maintain a screening log to 
record details of all participants screened a nd to confirm eligibility or record reasons for 
screening failure, as applicable. 
• Procedures conducted as part of the participant’s routine clinical management (eg, blood 
count) and obtained before signing of the ICF may be utilized for sc reening or baseline 
purposes provided the procedures met the prot ocol-specified criteria  and were performed 
within the timeframe defined in the SoA. 
• The maximum amount of blood collected for PK from each participant over the duration 
of the study, including any extra assessments that may be required, will not exceed 45 mL. 
Repeat or unscheduled samples may be taken for safety reasons or for technical issues 
with the samples. 
8.1. Efficacy Assessments 
Efficacy assessments are: mesopic and photopi c, high contrast DCNVA for each eye and 
binocularly, mesopic and photopic, high contrast  DCIVA for each eye and binocularly,
PRO questionnaires (NVPTQ, PI[CONTACT_16635],

 
 
Approval Date :  
 05-Dec-[ADDRESS_843378] 
DCNVA for each eye and 
binocularly 
 • Screening 
• Days 1, 14, and 30:  
Hours 0, 0.25, 0.5, 1, 3, 6, 8, and 10 
• Days 3 and 7:  
Hours 0, 1, and 3 
 • Visual acuity for near (40-cm), intermediate 
(66-cm) and distance (4-m eter) targets will be 
measured in mesopic and photopic conditions. 
• Mesopic condition is defined as lighting 3.2 to 3.5 candelas per square meter (cd/m
2; 10 to 
11 lux) measured at the target. 
Photopic condition is defined as lighting 
≥ 80 cd/m2 (251 lux) measured at the target. 
Photopic, high contrast DCNVA for each eye and binocularly 
 • Screening 
• Days 1, 14, and 30:  
Hours 0, 0.25, 0.5, 1, 3, 6, 8, and 10 
• Days 3 and 7:  
Hours 0, 1, and [ADDRESS_843379] DCIVA for 
each eye and binocularly • Screening 
• Days 1, 14, and 30:  
Hours 0, 1, 3, 6, 8, and 10 
• Days 3 and 7:  
Hours 0, 1, and 3   

 
 
Approval Date :  
 05-Dec-2018 
 Protocol 1883-301-013       
AGN-190584 
36 
Assessment Timing Measurement 
PRO Questionnaires  
Mesopic and Photopic 
NVPTQ  • Day 1, Hour 0 
• Day 14, Hour 1 
• Day 30, Hour 3 
 • Comprised of 12 questions on 4 reading tasks 
(ie, reading a paragrap h from a book, reading 
excerpts from an article in a newspaper, reading a portion of a nutrition label, and reading a section 
from a restaurant menu) 
• Participants will complete specific reading tasks 
under mesopic and photopic conditions without any near-vision correction  
• Participants will then answer 3 questions for each 
task, rating their vision-related reading ability and 
satisfaction with their vision-related reading 
ability 
• There is no explicit recall period used for the NVPTQ; the intention is for patients to complete 
the NVPTQ immediately after completing each 
task. 
• For more details on instructions and questions in 
NVPTQ, please see Appendix  8 
PI[CONTACT_16635]  • Day 1, Hour 0 
• Day 30, Hour 3 
 • Participants will answer 20 questions about the degree to which they were impacted by [CONTACT_631917] (eg, found daily near-
vision tasks difficult, or experienced self-consciousness); or engaged in copi[INVESTIGATOR_610] 
(eg, changed the font size  on electronic screens) 
during the previous 7 days 
• For more details on instructions and questions in 
PI[CONTACT_16635], please see Appendix 8  

 
 
Approval Date :  
 05-Dec-2018 
 Protocol 1883-301-013       
AGN-190584 
37 
8.2. Safety Assessments 
Planned timepoints for all safety assessm ents are provided in the SoA (Section 1.3). 
8.2.1.  Vital Signs 
Vital signs will be assessed as follows: 
• Blood pressure and pulse rate will be assessed. 
• Systolic and diastolic blood pressure will be measured using an appropriate 
sphygmomanometer after participants have been  at rest (seated) for at least 5 minutes. 
Blood pressure will be recorded in mm Hg. 
• Heart rate will be measured in bpm after the participant has been in a resting state (seated) for at least 5 minutes. Pulse will be counted for 30 seconds, multiplied by 2, and recorded 
in bpm. 
• Blood pressure and pulse measurements will be assessed with a completely automated 
device. Manual techniques will be used only if an automated device is not available. 
Manual techniques will be used  only by [CONTACT_28788]; whenever possible, 
the same person should perform all manua l assessments as much as possible. 
• Participants should refrain from smoking or  ingesting caffeine during the [ADDRESS_843380] result before receiving 

 
 
Approval Date :  
 05-Dec-[ADDRESS_843381] will also be performed at the Day 30 (Early Exit) visit, and may be 
performed at any other visit, at th e investigator’s discretion. At each  visit, the investigator should 
discuss cont raceptive use compliance with WOCBP. Additional details are provided in 
Appendix [ADDRESS_843382] CDVA, for each eye and binocularly, will be assessed using 
the provided visual acuity charts for distance vi sion in a room with mesopic lighting conditions 
(defined by [CONTACT_631918] 3.2 to 3.5 candelas [cd]/m2 [10 to 11 lux] measured at the target) and 
photopic lighting conditions  (defined by [CONTACT_631918] ≥ 80 cd/m2 [251 lux] measured at the target). 
Forced choice letter by-letter scoring will be used for each test and the total number of correct 
letters or the highest value (number) of the gr id identified (as applicable) will be recorded. 
Further details are outlined in the Procedure Manual. 
8.2.4.  Near Contrast Sensitivity 
Near contrast sensitivity assessment w ill be conducted under photopic conditions. A 
Pelli-Robson contrast sensitivity chart will be used . The logarithmic contrast sensitivity value of 
the last triplet of which at least [ADDRESS_843383] sensitivity. 
Further details are outlined in the Procedure Manual. 
8.2.5.  Study Intervention Tolerability and Drop Comfort Assessments 
The presence and severity of ocular symptoms will be elicited from the participant for both eyes 
after dosing. Symptoms, including blurred vision,  foreign body sensation, pain, burning/stinging, 
tearing, and itching, will be classified using a 5-point grading scale with 0 = none, +0.5 = trace, 
+1 = mild, +2 = moderate, and +3 = severe. The duration of symptoms (< 1 minute, 1 to 5 minutes, > 5 minutes) will be captured once immediately after the s econd eye is instilled 
with a drop of study intervention. If any other ocular symptoms are present, these will also be 
captured. 
Participants will be asked to rate the overall comfort of the eye drops using a 6-point scale (ie, 
soothing, very comfortable, comfortable, uncom fortable, very uncomfortable, and intolerable) 
immediately after the second eye is instilled with a drop of study intervention, for both eyes. 
8.2.6.  Temporal/Supraorbital Headac he Visual Analog Scale 
Participants will be asked to rate the degree of  temporal and supraorbital headache experienced 
after the second eye is in stilled with a drop of study intervention, for the right and left eyes 
separately. Headache will be reported on an unmarked 100-mm wide VAS, ranging from no pain 
on the left to worst possi ble pain on the right. 

 
 
Approval Date :  
 05-Dec-[ADDRESS_843384] anation tonometer affixed to a slit-lamp with 
the participant seated. The partic ipant and slit-lamp should be adju sted so that the participant’s 
head is firmly positioned on the chin rest and ag ainst the forehead rest without leaning forward 
or straining. Tight fitting neckwear should be l oosened. Both eyes will be tested, with the right 
eye preceding the left eye. The measurer will lo ok through the binocular viewer of the slit lamp 
at low power. The tension knob will be preset at a low-pressure value (4 to 6 mm Hg). The 
measurer will follow the image of the fluorescein stained semicircles while slowly rotating the 
tension knob until the inner borders of the fluores cein rings touch each other at the midpoint of 
their pulsation in response to the cardiac cycle. When this image is reached, the measurer will 
take his/her fingers off the tension knob and reco rd the IOP reading along with the date and time 
of day. 
8.2.8.  Slit-lamp Biomicroscopy 
Biomicroscopic examinations will be performed using a slit-lamp. The examinations will include 
evaluation of the condition of the eyelids, conjunctiva, cornea, an terior chamber, and iris/pupil. 

 
 
Approval Date :  
 05-Dec-2018 
 Protocol 1883-301-013       
AGN-190584 
40 
 
Eyelid/Eyelid Margins/Lashes: 
Edema   
  0 (None) = No edema 
+0.5 (Trace) = Localized, minimal (trace) swelling 
+1 (Mild) = Localized, mild swelling +2 (Moderate) = Diffuse, moderate swelling +3 (Severe) = Diffuse, severe swelling 
Erythema 
  
  0 (None) = No erythema 
+0.5 (Trace) = Localized, minima l (trace) flush reddish color  
+1 (Mild) = Localized, mild, flush reddish color +2 (Moderate) = Diffuse reddish color encompassing the entire lid margin 
+3 (Severe) = Deep diffuse reddish color of lid margins and superior 
and/or inferior eyelid 
Conjunctiva (Bulbar): 
Hyperemia 
 
  0 (None) = No hyperemia 
+0.5 (Trace) = Minimal (trace) flush, reddish color 
+1 (Mild) = Mild flush, reddish color 
+2 (Moderate) = Bright red color +3 (Severe) = Deep, bright diffuse redness 
Edema 
 
  0 (None) = No edema 
+0.5 (Trace) = Localized, minimal (trace) swelling 
+1 (Mild) = Localized, mild swelling +2 (Moderate) = Diffuse, moderate swelling +3 (Severe) = Diffuse, severe swelling 

 
 
Approval Date :  
 05-Dec-2018 
 Protocol 1883-301-013       
AGN-190584 
41 
 
Conjunctiva (Palpebral): 
Hyperemia  
  0 (None) = No hyperemia 
+0.5 (Trace) = Minimal (trace) flush, reddish color 
+1 (Mild) = Mild flush, reddish color 
+2 (Moderate) = Bright red color +3 (Severe) = Deep, bright diffuse redness 
Edema 
 
  0 (None) = No edema 
+0.5 (Trace) = Localized, minimal (trace) swelling 
+1 (Mild) = Localized, mild swelling +2 (Moderate) = Diffuse, moderate swelling 
+3 (Severe) = Diffuse, severe swelling 
Cornea: 
Edema 
 
  0 (None) = No edema 
+0.5 (Trace) = Localized, mini mal (trace) epi[INVESTIGATOR_42247] 
+1 (Mild) = Dull glass appearance of epi[INVESTIGATOR_631891] 
+2 (Moderate) = Dull glass appearance of the epi[INVESTIGATOR_631892] 
 +3 (Severe) = Epi[INVESTIGATOR_86148] a nd/or stromal edema, localized or 
diffuse, with or without stromal striae 
Superficial Punctate Keratopathy 
 0 = No superficial punctate keratopathy +0.5 = Trace 
+1 = Mild 
+2 = Moderate 
+3 = Severe 
Anterior Chamber: 
The anterior chamber will be evalua ted for pathology. If pathology is present, it will be described. 

 
 
Approval Date :  
 05-Dec-2018 
 Protocol 1883-301-013       
AGN-190584 
42 
 
Iris/Pupil: 
The iris/pupil will be evaluated for pathology. If pathology is present,  it will be described. 
8.2.9.  Manifest Refraction 
Manifest refraction (distance and near) will be performed according to standard clinical practice 
in both mesopic and photopic conditions. 
If a participant loses ≥ [ADDRESS_843385] refrac tion should be repeated under the same lighting 
conditions. Additional details are outlined in the Procedure Manual. 
8.2.10. Dilated Funduscopic Examination 
The fundus assessments should be conducted th rough a dilated pupil. The examinations will 
include evaluation of the lens, vitreous, fundus, and optic nerve. The C/D ratio will be assessed. 
The investigator should note if the pupil dilated normally. 
Lens: 
Lens Assessment: 
Use biomicroscopic examination, indirect lens es, direct/indirect ophthalmoscopy, etc., as 
appropriate, to visualize. Lens Status: The lens will be evaluated for pathology. If pathology is present, it will be described. 
Cataract Assessment: Under dilated examination, the presence and se verity of nuclear, co rtical, and posterior 
subcapsular cataract lens opacities will be evaluate d. At the first dilated examination, each type 
of cataract, if present, will be graded using the scale below. At the last follow-up dilated 
examination, each type of cataract will be assessed for change from baseline and if changed, the 
current severity will be graded using the scale below: 
 0 = None 
+1 = Mild 
+2 = Moderate 
+3 = Severe 
Vitreous: 
The vitreous will be evaluated for pathology. If pa thology is present, it will be described. It will 
be noted if the condition is not evaluable. 

 
 
Approval Date :  
 05-Dec-2018 
 Protocol 1883-301-013       
AGN-190584 
43 
 
Fundus: 
The fundus (posterior pole; periphery, when d ilated) will be evaluated for pathology. If 
pathology is present, it will be described. It w ill be noted if the condition is not evaluable. 
Optic Nerve: The optic nerve will be evaluated for pathology. If pathology is present, it will be described. It 
will be noted if the condition is not evaluable. 
C/D Ratio: 
C/D ratio will be reported using a 0.0 to 1.0 scal e. It will be noted if the condition is not 
evaluable. 
8.2.11. Suicidal Risk Monitoring 
Suicidal risk monitoring is not ap plicable to this ophthalmology study. 
8.3. Adverse Events and S erious Adverse Events 
The definitions of an AE or SAE can be found in Appendix 2. 
AEs will be reported by [CONTACT_2299] (or, wh en appropriate, by a caregiver, surrogate, or the 
participant’s legally authorized representative). 
The investigator and any qualified designees ar e responsible for detecting, documenting, and 
recording events that meet the definition of an  AE or SAE and remain responsible for following 
up AEs that are serious, considered related to th e study intervention or study procedures, or that 
caused the participant to discont inue the study intervention (ie, repeat treatment) or study (see 
Section 7). 
8.3.1.  Time Period and Frequency for Collecting Adverse Event and Serious Adverse 
Event Information 
All SAEs from the signing of the ICF until [ADDRESS_843386] dose of study intervention will 
be collected at the timepoints specified in the So A (Section 1.3 ), and as observed or reported 
spontaneously by [CONTACT_19288]. 
All AEs from the signing of the ICF until [ADDRESS_843387] dose of study interven tion will be 
collected at the tim epoints specified in the SoA (Section 1.3), and as observed or reported 
spontaneously by [CONTACT_19288]. Medical occurrences that begin before the start of study intervention, but after obtaining 
informed consent will be recorded  in the AE section of the eCRF. 
All SAEs will be record ed and reported to the sp onsor or designee within 24 hours, as indicated 
in Appendix 2 . The investigator will submit any update d SAE data to the sponsor within 
24 hours of it being available. 

 
 
Approval Date :  
 05-Dec-2018 
 Protocol 1883-301-013       
AGN-190584 
44 
 
Investigators are not obligated to  actively seek AE or SAE information after conclusion of the 
study participation. However, if the investigator learns of any SAE, including a death, at any 
time after a participant has been discharged from the study, and he/she cons iders the event to be 
reasonably related to the study intervention or study participation, the investigator must promptly 
notify the sponsor. 
The methods of recording, evaluating, and assess ing causality of AEs and SAEs and the 
procedures for completing and transmitting SAE reports are provided in Appendix 2. 
8.3.2.  Method of Detecting Adverse Events and Serious Adverse Events 
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open-ended and 
non-leading verbal questioning of  the participant is the preferred method to inquire about 
AE occurrences. 
8.3.3.  Follow-up of Adverse Events and Serious Adverse Events 
After the initial AE/SAE report, the investigator is required to proactively follow each participant 
at subsequent visits/contacts. All AEs/SAEs will be followed until resolution, stabilization, the 
event is otherwise explained, or the participan t is lost to follow-up (as defined in Section 7.3). 
The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indi cated or as requested by [CONTACT_631919]/or causality of the AE or SAE as  fully as possible. This may include additional 
laboratory tests or investigati ons, histopathological examinati ons, or consultation with other 
health care professionals. 
If a participant dies during participation in the study, the investigator will  provide Allergan with 
a copy of any postmortem findings including histopathology. 
If a participant is hospi[INVESTIGATOR_213572], follow-up attempts must be made to obtain the 
discharge summary from the hospi[INVESTIGATOR_3491], if obtained, it should be sent to the sponsor. 
New or updated information will be record ed in the originally completed eCRF. 
The investigator will submit any updated SAE data to Allergan within 24 hours of receipt of the 
information. 
8.3.4.  Regulatory Reporting Requirements for Serious Adverse Events 
• Prompt notification by [CONTACT_78574] 
a study intervention under clinic al investigation are met.  
• The sponsor has a legal responsibility to notify both the local regulatory authority and other regulatory agencies about the safe ty of a study intervention under clinical 
investigation. The sponsor will comply w ith country-specific regulatory requirements 
relating to safety reporting to the regulatory authority, IRBs/IECs, and investigators.  

 
 
Approval Date :  
 05-Dec-2018 
 Protocol 1883-301-013       
AGN-190584 
45 
 
• Investigator safety reports must be prepared for suspected unexpected serious adverse 
reactions according to local re gulatory requirements and sponsor policy and forwarded to 
investigators as necessary. 
• An investigator who receives an investigator  safety report describing an SAE or other 
specific safety information (eg, summary or listing of SAEs) from th e sponsor will review 
and then file it along with the IB and will not ify the IRB/IEC, if appropriate according to 
local requirements. 
8.3.5.  Pregnancy 
• If a pregnancy is confirmed after the partic ipant has received the study intervention, the 
participant may choose to exit the study after appropriate safety follow-up or to remain in 
the study for all safety and efficacy follow-up assessments through the EOS visit. 
• Details of all pregnancies in female participants and, if indicated, female partners of male participants will be collected after the start of study intervention and through the duration 
of the pregnancy . 
• If a pregnancy is reported, the investigator  should inform Allergan within 24 hours of 
learning of the pregnancy and should follow the procedures outlin ed in Appendix 6.  
• Abnormal pregnancy outcomes (eg, spontaneous abortion, fetal death, stillbirth, congenital anomalies, ectopic pregnancy) or ge netic abnormalities (whether leading to an 
elective abortion or not) are considered SAEs. 
8.3.6.  Medication Errors 
Medication error refers to any unintended error in the dosing and/or administration of the study 
intervention as per instructions in the protocol. Medication errors  generally fall into 4 categories 
as follows: 
• Wrong study drug 
• Wrong dose (including dosing regimen, st rength, form, concentration, amount) 
• Wrong route of administration 
• Wrong participant (ie, not administer ed to the intended participant) 
8.4. Treatment of Overdose 
Treatment of overdose is not applic able to this ophthalmology study. 

 
 
Approval Date :  
 05-Dec-2018 
 Protocol 1883-301-013       
AGN-190584 
46 
 
8.5. Pharmacokinetics 
Blood samples for quantitation of pi[INVESTIGATOR_631893]’s plasma will be collected from 
approximately 10% of enrolled participants at selected sites. 
8.5.1.  Blood Pharmacokinetic Sampling Procedure 
• A qualified phlebotomist will coll ect 5 mL of each participant’s blood via an indwelling 
catheter or venipuncture from either arm in to one 6 mL vacutainer tube containing 
K2EDTA as an anticoagulant.  
• Plasma samples of approximately 2.5 mL will be separated from each blood sample 
collected for measurement of plasma concentra tions of pi[INVESTIGATOR_631894] 
(Section 1.3). 
• Instructions for the collection and handling of biological samples will be provided by 
[CONTACT_78562]. The actual date and time (24-hour clock time) of each sample will be recorded. 
PK blood samples to determine pi[INVESTIGATOR_631895], relative to the dosing time, and the actu al time of the blood draw must be recorded 
in the source documents and eCRFs. Samples taken outside the allowable time window 
will be noted as protocol deviations, and the reason for deviation must be recorded in the 
source documents and eCRFs. Predose samples must be drawn within 15 minutes of the 
dosing time.  
• Study center staff will record the atomic clock times of all blood draws for each 
participant and will label vacutainer and polypropylene tubes with a coded label that corresponds to the participant number and blood draw time. The central lab will supply 
the coded labels, vacutainers, and polypropylene tubes. The study center will be 
responsible for all other supplies.  
• Samples will be used to evaluate the pha rmacokinetics of pi[INVESTIGATOR_1227]. Each plasma 
sample will be divided into 2 aliquots (1  each for primary and backup PK samples). 
Samples collected for analyses of pi[INVESTIGATOR_631896].  
Drug concentration information that would unmask the study will not be reported to investigative 
sites or blinded personnel unt il the study has been unmasked. 
Bioanalytical representatives will be unmasked for PK sample bioanaly sis during the conduct of 
the study. The unmasking of bioanalytical representa tives is to be carried out in a secure manner 
following Allergan’s standard operating procedures . Extreme care and diligence will be taken to 
ensure no other individuals outside the bioanalytical team will be unblinded. 

 
 
Approval Date :  
 05-Dec-2018 
 Protocol 1883-301-013       
AGN-190584 
47 
 
Blood Volume Collected per Participant  
• Approximately 10% of participants at selected sites  
• PK blood samples: 45 mL (9 blood samples, 5 mL each) 
Within [ADDRESS_843388] be centrifuged at no less 
than 2000 g for 15 minutes at approximately 4°C. After centrifugation, the plasma samples will 
be harvested and aliquoted into two approximate ly 1.25 mL samples in cryovials (one primary 
and one backup). The samples should be placed on wet ice immediately after aliquoting and 
transferred to a –20°C freezer within one hour of processing to plasma. 
Study center staff will send plasma samples to th e central lab for storage at the end of each 
period. Before shipment and on the day of ship ment, the sponsor and th e central lab will be 
notified by [CONTACT_631920]. Primary and backup samples will be 
shipped to the central lab in sepa rate shipments on separate days. 
8.5.2.  Pharmacokinetic Sample Bioanalysis 
Plasma concentrations of pi[INVESTIGATOR_631897]-tandem mass spectrometry methods. 
8.6. Pharmacodynamics 
Pharmacodynamic parameters are not evaluated in this study. 
8.7. Genetics 
Genetics are not evaluated in this study. 
8.8. Biomarkers and Other Assessments 
8.8.1.  Biomarkers 
Biomarkers are not evaluated in this study. 
8.8.2.  Determination of Dominant Eye 
Participants will be asked to extend their arms out in front of them at eye level, with their palms 
facing away, fingers together, and facing upward. Participants will bring their hands together, 
forming a small window by [CONTACT_249983][INVESTIGATOR_631898]. Participants 
will select a small object at least [ADDRESS_843389], participants will close the 
right eye and take note of whether the image rema ins visible. If the image remains visible, the 
left eye is the dominant eye. If the image is no longer visible, the right eye is the dominant eye. 
This will be confirmed by [CONTACT_631921] e and taking note of whether the image remains 
visible. Details will be outlined in the Procedure Manual. 

 
 
Approval Date :  
 05-Dec-2018 
 Protocol 1883-301-013       
AGN-190584 
48 
 
8.9. Health Economics 
PRO instruments (questionnaires ) are administered in this study
At screening, participants will answer questions on vision functioning and health-related quality 
of life using the NEI VFQ-25, in cluding the near vision subscale  items (Questions A3 to A5) 
from the Appendix of Optional Additional Questions. 
Each participant will also pe rform four different near vision reading tasks under mesopic and 
photopic conditions. Participants will subsequently  rate their vision-rela ted reading ability, and 
satisfaction with their vision-rela ted reading ability on the NVPTQ. 
Participants will also answer questions measuri ng overall satisfaction with the treatment using 
questions assessing the impact  of presby[CONTACT_631922] – and need for 
compensatory copi[INVESTIGATOR_90359] – using the PI[CONTACT_16635]. 
9. Statistical Considerations 
9.1. Statistical Hypotheses 
The null and alternative hypotheses for the primary efficacy endpoint are: 
• H0: AGN-[ADDRESS_843390], binocular DCNV A at Day 30, Hour 3; 
• HA: AGN-[ADDRESS_843391], binocul ar DCNV A at Day 30, Hour 3. 
The null and alternative hypotheses for th e key secondary efficacy endpoint are: 
• H0: AGN-[ADDRESS_843392], binocular DCNV A at Day 30, Hour 6; 

 
 
Approval Date :  
 05-Dec-2018 
 Protocol 1883-301-013       
AGN-190584 
49 
 
• HA: AGN-[ADDRESS_843393] is assumed to be 3.6%, as observed in 
the Phase [ADDRESS_843394] is assume d to be 16% in emmetropes and 12% in non-
emmetropes. This gives an overall AGN-[ADDRESS_843395] of 15% assuming emmetropes will be 
75% of the study population. [ADDRESS_843396] the above difference with a pow er of 90% or greater at the 2-sided 
5% significance level. Assuming a 10% dropout rate, approximately [ADDRESS_843397] of  participants as defined below: 
• The ITT population includes all randomized par ticipants. Participants will be summarized 
according to the randomized study intervention. 
• The safety population includes all treated participants who receive ≥ [ADDRESS_843398] dose of study interven tion. All statistical 
tests will be 2-sided hypothesis te sts performed at the 5% level of  significance for main effects. 
All confidence intervals will be 2-sided 95% conf idence intervals, unless stated otherwise.  

 
 
Approval Date :  
 05-Dec-2018 
 Protocol 1883-301-013       
AGN-190584 
50 
 
[IP_ADDRESS]. Analysis Endpoints 
The primary and secondary efficacy endpoints are lis ted below and analyses will be described in 
the following sections. The analyses for other efficacy endpoints listed below will be described 
in the SAP. 
Primary Efficacy Endpoint: 
• Proportion of participants gaining [ADDRESS_843399], binocular 
DCNV A at Day 30, Hour 3. 
Key Secondary Efficacy Endpoint: 
• Proportion of participants gaining [ADDRESS_843400], binocular 
DCNV A at Day 30, Hour 6. 
Secondary Efficacy Endpoints: 
1. Proportion of participants gaining 3-lines or more in mesopic, high contrast, binocular, 
DCNV A at Day 30, Hour 8. 
2. Change from baseline mesopic, high contrast, binocular DCNV A letters at Day 30, 
Hour 0.5. 
3. Proportion of participants achieving 20/[ADDRESS_843401], binocular DCNV A letters at Day 30, Hour 0.25.  
8. Proportion of participants achieving 20/[ADDRESS_843402] score mean change from baseline at Day 30, Hour 3. 

 
 
Approval Date :  
 05-Dec-2018 
 Protocol 1883-301-013       
AGN-190584 
51 
 
[IP_ADDRESS]. Primary Analyses 
The proportion of participants gaining [ADDRESS_843403]. Missing data will be regarded 
as 3-line gain failure. 
[IP_ADDRESS]. Secondary Analyses 
The key secondary efficacy endpoint is the proporti on of participants gaining [ADDRESS_843404]. Secondary endpoints 
2, 4, 5, and 7 will be analyzed using MMRM with study intervention group, visit, visit by [CONTACT_631923], age group, baseline binocular DCNVA severity, iris color, 
emmetropes/non-emmetropes, baseline value, and baseline value by [CONTACT_631924]. The within-participant co rrelation error struct ure is unstructured. Secondary endpoints 9, 
10, and 11 will be analyzed using analysis of covariance with study intervention group, age 
group, baseline binocular DCNVA severity, iris color, emmetropes/non-emmetropes, and 
baseline domain score as fixed effects. 
To control the overall Type [ADDRESS_843405] atistically significant. A proper 
multiple comparison procedure will be pre-specified in the SAP. 
9.4.2.  Safety Analyses 
The safety analysis will be performed using the sa fety population and will be fully defined in the 
SAP. The safety parameters will include AEs,  vital signs (blood pressure and heart rate), 
mesopic and photopic, high contrast, binocular CDVA, near contrast sensitivity, study 
intervention tolerability and drop comfort a ssessments, temporal/supraorbital headache 
assessment using VAS, IOP, slit-lamp biomicrosc opy, manifest refraction, dilated funduscopic 
examination, and pregnancy test. For each sa fety parameter, the last nonmissing safety 
assessment before the first dose of study inte rvention will be used as the baseline. 

 
 
Approval Date :  
 05-Dec-2018 
Protocol 1883-301-013       
AGN-190584 
52 
 
[IP_ADDRESS]. Adverse Events 
An AE will be considered a TEAE if the AE began or worsened (increased in severity or became 
serious) on or after the date of the first dose of study intervention.  However, an AE that occurs 
more than [ADDRESS_843406] related occurrence for the summarizations by [CONTACT_325747]. 
Summary tables will be provided fo r participants with SAEs and pa rticipants with AEs leading to 
discontinuation if 5 or more participants reported  such events. Listings of all AEs, SAEs, and 
AEs leading to discontinuation by [CONTACT_325748]. 
[IP_ADDRESS]. Other Safety Analyses 
All other safety variables will be analyzed with descriptive statistics. Detailed methods for the 
analysis of other safety variable s will be described in the SAP. 
9.4.3.  Pharmacokinetic Analyses 
[IP_ADDRESS]. Pharmacokinetic Parameters 
The following PK parameters will be calculated based on standard Phoenix WinNonlin 
equations: AUC
0-last.ss , maximum plasma drug concentration at steady state, time of maximum 
plasma drug concentration at steady state, C min,ss, and peak-to-trough ratio. 
Cmin,ss will be determined observationally as the drug concentration during the dosing interval at 
steady state. 
AUC 0-last,ss  will be calculated by [CONTACT_143624]-log trapezoidal rule. 
[IP_ADDRESS]. Statistical Analyses of  Pharmacokinetic Data 
Details of the statistical analyses of PK data will be described in the pharmacokinetic analysis 
plan finalized before database lock.  

 
 
Approval Date :  
 05-Dec-2018 
Protocol 1883-301-013       
AGN-190584 
53 
 
9.5. Interim Analyses 
No interim analysis is planned. 
9.5.1.  Data Monitoring Committee 
Not applicable. 

 
 
Approval Date :  
 05-Dec-2018 
Protocol 1883-301-013       
AGN-190584 
54 
 
10. Supporting Documentation and Operational Considerations 

 
 
Approval Date :  
 05-Dec-2018 
Protocol 1883-301-013       
AGN-190584 
55 
 
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight 
Considerations 
10.1.1. Regulatory and Ethical Considerations 
• This study will be conducted in accordance w ith the protocol and with the following: 
o Consensus ethical principles derived fr om international gui delines including the 
Declaration of Helsinki and Council for International Organi zations of Medical Sciences 
International Ethical Guidelines 
o Applicable ICH/International Organiza tion for Standardization GCP guidelines 
o Applicable laws and regulations 
• The protocol, protocol amendments, ICF, IB, and other relevant documents (eg, 
advertisements) must be submitted to an IRB/IEC by [CONTACT_112245]/IEC before the study is initiated. 
• Any amendments to the protocol will requir e IRB/IEC approval before implementation of 
changes made to the study design, except for changes necessary to e liminate an immediate 
hazard to study participants.  
• The investigator will be re sponsible for the following: 
o Providing written summaries of the status of  the study to the IRB/IEC annually or more 
frequently in accordance with the requirements, policies, and procedures established by [CONTACT_1201]/IEC 
o Notifying the IRB/IEC of SAEs or other sign ificant safety findings as required by 
[CONTACT_1744]/IEC procedures 
o Providing oversight of the overall conduct of the study at the site and adherence to 
requirements of applicable local regulations, for example 21 CFR, ICH guidelines, the IRB/IEC, and European regulation 536/2014 for clinical studies (if applicable) 

 
 
Approval Date :  
 05-Dec-2018 
Protocol 1883-301-013       
AGN-190584 
56 
 
10.1.3. Informed Consent Process 
• The investigator or his/her representative will explain the nature  of the study to the 
participant or his/her legally authorized repres entative and answer all questions regarding the 
study.  
• Participants must be informed that their part icipation is voluntary. Participants will be 
required to sign a statement of informed consent that meets the requirements of [ADDRESS_843407] 
requirements, where applicable, and the IRB/IEC or study center.  
• The medical record must include a statement that written informed consent was obtained 
before the participant was enrolled in the study and the date the written consent was obtained. The authorized person obtain ing the informed consent must also sign the ICF. 
• Participants must be re-consented to the most  current version of th e ICF(s) during their 
participation in the study.  
• A copy of the ICF(s) must be provided to the participant or the participant’s legally 
authorized representative. 
10.1.4. Data Protection 
• Participants will be assigned a unique identifier . Any participant records or datasets that are 
transferred to the sponsor will contain the identifier only; participant names or any 
information which would make the participan t identifiable will not be transferred.  
• The participant must be informed that his/her personal study-related data will be used by [CONTACT_89192]. The level of disc losure must also be 
explained to the participant.  
• The participant must be informed that his/her medical records may be examined by [CONTACT_325751], by 
[CONTACT_6667]/IEC members, and by [CONTACT_325752]. 
10.1.5. Posting Clinical Study Data 
• Study data and information may be published in  nonpromotional, peer-reviewed publications 
either by [CONTACT_82298].  
• Clinical study reports, safety updates, and a nnual reports will be pr ovided to regulatory 
authorities as required. 
• Company-sponsored study information and tabul ar study results will be posted on the United 
States National Institutes of Health's we bsite www.ClinicalTrials .gov and other publicly 
accessible sites 

 
 
Approval Date :  
 05-Dec-2018 
Protocol 1883-301-013       
AGN-190584 
57 
 
10.1.6. Data Quality Assurance 
• All participant data relating to the study will be recorded on printed or electronic CRFs 
unless transmitted to the sponsor or designee electronically (eg, laboratory data). The 
investigator is responsible for verifying th at data entries are a ccurate and correct by 
[CONTACT_208572].  
• The investigator must maintain accurate do cumentation (source data) that supports the 
information entered in the CRF.  
• The investigator must permit study-related monitoring, audits, IRB/IEC review, and 
regulatory agency inspections and provide direct access to source data documents.  
• The sponsor or designee is res ponsible for the data management of this study including 
quality checking of the data.  
• Study monitors will perform ongoing source data verification to confirm that data entered 
into the CRF by [CONTACT_325753], complete, and verifiable from source 
documents; that the safety and rights of participants are being protected; and that the study is 
being conducted in accordance with the curren tly approved protocol and any other study 
agreements, ICH GCP, and all app licable regulatory requirements.  
• Records and documents, including signed ICFs, pe rtaining to the conduct of this study must 
be retained by [CONTACT_325754] e clinical trial agreement. No records may be 
destroyed during the retention period without the written approval of the sponsor. No records 
may be transferred to another location or part y without written notification to the sponsor.  
10.1.7. Source Documents 
• Source documents provide evidence for the existe nce of the participant and substantiate the 
integrity of the data collected. Source documents are filed at the investigator’s site. 
• Data reported on the CRF or entered in the e CRF that are transcribed from source documents 
must be consistent with the source documents or the discrepancies must be explained. The 
investigator may need to request previous medi cal records or transfer  records, depending on 
the study. 
• Definition of what constitutes source data can  be found in Section 4.0 of ICH E6, GCP: 
Consolidated Guidance and records must be attributable, legible, cont emporaneous, original, 
and accurate. 

 
 
Approval Date :  
 05-Dec-2018 
Protocol 1883-301-013       
AGN-190584 
58 
 
10.1.9. Publication Policy 
• Allergan as 
the sponsor has proprietary intere st in this study. Authorship and manuscript 
composition will reflect joint cooperation betw een multiple investig ators and sites and 
Allergan personnel. Authorship will be establis hed prior to the writing of the manuscript. As 
this study involves multiple centers, no individu al publications will be allowed prior to 
completion of the final report of the multicen ter study except as agreed with Allergan. 
• The sponsor will comply with the requirem ents for publication of study results. In 
accordance with standard editorial and ethical practice, the sponsor will generally support 
publication of multicenter studies only in their entirety and not as individual site data. 
• Authorship will be determined by [CONTACT_325756]. 
10.1.10. Compliance with Protocol 
The investigator is responsible for compliance wi th the protocol at the investigational site. A 
representative of the sponsor will make freque nt contact [CONTACT_78586]/her 
research staff and will conduct regular monitoring visits at the site to review participant and 
study intervention accountability records for complia nce with the protocol. Protocol deviations 
will be discussed with the investigator upon identification. The use of the data collected for the 
participant will be discussed to determine if th e data are to be included in the analysis. The 
investigator will enter data that may be excl uded from analysis as defined by [CONTACT_78587]. Signifi cant protocol deviations will  be reported to the IRB/IEC 
according to the IRB/IEC’s reporting requirements. 

 
 
Approval Date :  
 05-Dec-2018 
Protocol 1883-301-013       
AGN-190584 
59 
 
10.2. Appendix 2: Adverse Events: De finitions and Procedures for 
Recording, Evaluating, Follow-up, and Reporting 
Definition of AE 
AE Definition 
• An AE is any untoward medical occurrence in  a patient or clini cal study participant, 
temporally associated with the use of st udy intervention, whether or not considered 
related to the study intervention. 
• An AE can therefore be any unfavorable and unintended sign (including an abnormal 
laboratory finding), symptom, or disease (new or exacerbated) temporally associated 
with the use of study intervention. 
AESI  
An AESI (serious or nonserious) is one of sc ientific and medical concern specific to the 
sponsor’s study drug/device or program, wh ich warrants ongoing monitoring and rapid 
communication by [CONTACT_68477]. Such an event might warrant further investigation in or der to characterize  and understand it.  
There are no AESIs identified for the study intervention AGN-190584. 
 
Events Meeting the AE Definition  
• Exacerbation of a chronic or intermittent pre-existing condition including either an 
increase in frequency and/or intensity of the condition 
• New condition detected or diagnosed afte r study intervention administration even 
though it may have been present before the start of the study 
• Signs, symptoms, or the clinical sequel ae of a suspected drug-drug interaction 
• Lack of efficacy or failure of expected pharmacological action per se will not be reported as an AE or SAE. Such instances will be captured in the efficacy 
assessments. However, the signs, symptoms, and/or clinical sequelae resulting from the lack of efficacy will be reported as AEs or  SAEs if they fulfill the definition of an 
AE or SAE. 
 

 
 
Approval Date :  
 05-Dec-2018 
Protocol 1883-301-013       
AGN-190584 
60 
 
Events NOT Meeting the AE Definition  
• Any clinically significant abnormal laborat ory findings or other abnormal safety 
assessments that are associated with the underlying disease or disease progression, 
unless judged by [CONTACT_631925]’s condition. Merely repeating an  abnormal test, in the absence of any of 
the above conditions. Any abnormal test result that is determined to be an error does 
not require recording as an AE. 
• Medical or surgical procedure (eg, e ndoscopy, appendectomy): the condition that 
leads to the procedure is the AE 
• Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]) 
• Anticipated day-to-day fluctuations of pre-existing disease(s) or condition(s) present 
or detected at the start of the study that do not worsen 
Definition of SAE 
SAEs must meet both the AE criteria described a bove and the seriousness criteria listed below. 
An SAE is defined as any untoward medical occurrence that, at any dose: 
a. Results in death 
b. Is life threatening 
The term life threatening  in the definition of serious  refers to an event in which the 
participant was at risk of death at the time of  the event. It does not refer to an event, 
which hypothetically might have caused death, if it were more severe. 
c. Requires inpatient hospi[INVESTIGATOR_9234], hospi[INVESTIGATOR_19949] (usually 
involving at least an overnight stay) at th e hospi[INVESTIGATOR_12332]/or intervention that would not have b een appropriate in th e physician’s office or 
outpatient setting. Complications that o ccur during hospi[INVESTIGATOR_1084]. If a 
complication prolongs hospi[INVESTIGATOR_219858], the event is 
serious. When in doubt as to whether hospi[INVESTIGATOR_631899] s necessary, the AE 
should be considered serious. 
Hospi[INVESTIGATOR_287408] a pre-existing condition that did not worsen 
from baseline is not considered an AE. 

 
 
Approval Date :  
 05-Dec-2018 
Protocol 1883-301-013       
AGN-190584 
61 
 
d. Results in persistent disability/incapacity 
• The term disability means a substantial disruption of a person’ s ability to conduct 
normal life functions. 
• This definition is not intended to include experiences of relatively minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, and accidental trauma (eg, sprained ankle) which may interfere with or prevent everyday life functions but do not constitute a substantial disruption.
 
e. Is a congenital anomaly/birth defect 
f. Other situations: 
• Medical or scientific judgment should be exercised in deciding whether SAE reporting is appropriate in othe r situations such as important medical events that may 
not be immediately life threatening or result in death or hos pi[INVESTIGATOR_631900]. These events should usually be considered serious. 
Examples of such events include inva sive or malignant cancers, intensive 
intervention in an emergency room or at home for allergic bronchospasm, blood 
dyscrasias or convulsions that do not result  in hospi[INVESTIGATOR_059], or development of 
drug dependency or drug abuse.
 
Recording and Follow-Up of AEs and/or SAEs 
AE and SAE Recording 
• When an AE or SAE occurs, it is the respons ibility of the investig ator to review all  
documentation (eg, hospi[INVESTIGATOR_1088] , laboratory reports, and diagnostics 
reports) related to the event. 
• The investigator will then record all rele vant AE or SAE information in the eCRF. 
• It is not acceptable for the investigator to send photocopi[INVESTIGATOR_10914]’s 
medical records to Allergan in lieu of completion of the AE or SAE eCRF page. 
• There may be instances when copi[INVESTIGATOR_631901]. In this case, all par ticipant identifiers, with the exception of 
the participant number, will be redacted on the copi[INVESTIGATOR_631902]. 
• The investigator will attempt to establish a diagnosis of the event based on signs, symptoms, and/or other clinical informati on. Whenever possible, the diagnosis (not 
the individual signs/symptoms) will be documented as the AE/SAE.
 

 
 
Approval Date :  
 05-Dec-[ADDRESS_843408] one of the predefined outcomes as 
described in the definition of an SA E, NOT when it is rated as severe. 
 
Assessment of Causality 
• The investigator is obligated to assess the relationship betw een study intervention 
and each occurrence of each AE or SAE. 
• A reasonable possibility  of a relationship conveys th at there are facts, evidence, 
and/or arguments to suggest a causal rela tionship, rather than a relationship cannot 
be ruled out. 
• The investigator will use clinical judgment to determine the relationship. 
• Alternative causes, such as underlying dis ease(s), concomitant therapy, and other 
risk factors, as well as the temporal re lationship of the event to study intervention 
administration will be considered and investigated. 
• The investigator will also consult the IB and/or product information, for marketed 
products, in his/her assessment. 
• For each AE or SAE, the investigator must  document in the medical notes that 
he/she has reviewed the AE or SAE and has provided an assessment of causality. 
• There may be situations in which an SAE has occurred and the investigator has 
minimal information to include in the initial report to Allergan. However, it is very 
important that the investigator always  make an assessment of causality for 
every event before the initial transmis sion of the SAE data to Allergan. 
• The investigator may change his/her opi [INVESTIGATOR_9242]-up 
information and send an SAE follow-up report with the updated causality 

 
 
Approval Date :  
 05-Dec-2018 
Protocol 1883-301-013       
AGN-190584 
63 
 
assessment. 
• The causality assessment is one of the criteria used when determining regulatory 
reporting requirements.  
Reporting of SAEs 
SAE/SADE Reporting 
• Email is the preferred met hod to transmit SAE information. The email address is 
[EMAIL_1588]. 
• Facsimile transmission of the SAE informati on is also acceptable. The fax number is 
+[PHONE_1850] (backup number is +[PHONE_1851]).  
• In rare circumstances and in the absence of facsimile equipm ent, notification by 
[CONTACT_9337] a copy of the SAE form, sent by [CONTACT_20022]. 
• Initial notification via tele phone does not replace the need  for the investigator to 
complete and sign the SAE form within the designated reporting time frames. 
• Contacts for SAE reporting can be found on the protocol title page.  
 

 
 
Approval Date :  
 05-Dec-2018 
Protocol 1883-301-013       
AGN-190584 
64 
 
10.3. Appendix 3: Abbreviations 
Abbreviation/Term Definition 
AE adverse event 
AESI adverse event of special interest 
AUC 0-last,ss  area under the plasma concentration versus time curve from time [ADDRESS_843409] 
measurable concentra tion, at steady state 
bpm beats per minute 
C/D cup to disc 
CDISC Clinical Data Interchange Standards Consortium 
CDVA corrected distance visual acuity 
CFR Code of Federal Regulations 
Cmin,ss minimum plasma drug concentration at steady state  
CRF case report form 
DCIVA distance-corrected in termediate visual acuity 
DCNVA distance-corrected near visual acuity 
DET dry eye test 
eCRF electronic case report form 
EOS end of the study 
FDA Food and Drug Administration 
FSH follicle-stimulating hormone 
GCP Good Clinical Practice 
HRT hormonal replacement therapy 
IB Investigator's Brochure 
ICF informed consent form 
ICH International Council for Harmonization 
ID identification 
IEC independent ethics committee 
IOP intraocular pressure 
IRB institutional review board 
ITT intent-to-treat 
IxRS interactive electronic response system 
LASIK laser-assisted in situ keratomileusis  
MMRM mixed model repeated measure 
NCI National Cancer Institute 
NEI VFQ-25 National Eye Institute Visual Function Questionnaire 25 
NVPTQ Near Vision Presby[CONTACT_631926]-based Questionnaire  
OD right eye 
OS left eye 
OSDI Ocular Surface Disease Index 

 
 
Approval Date :  
 05-Dec-2018 
Protocol 1883-301-013       
AGN-190584 
65 
 
Abbreviation/Term Definition 
PI[INVESTIGATOR_631903] d Copi[INVESTIGATOR_631904]-emergent adverse event 
VAS visual analog scale 
WOCBP women of childbearing potential 
 

 
 
Approval Date :  
 05-Dec-2018 
Protocol 1883-301-013       
AGN-190584 
66 
 
10.4. Appendix 4: Standard Discontinuation Criteria 
CDISC Submission Value CDISC Definition 
AE Any untoward medical occu rrence in a patient or 
clinical investigation subject administered a 
pharmaceutical product and which does not 
necessarily have a causal relationship with this 
treatment. An AE can therefore be any unintended 
sign (including an abnormal laboratory finding), 
symptom, or disease tempor ally associated with the 
use of a medicinal (investigational) product, 
whether or not related to the medicinal 
(investigational) product. For further information, 
see the ICH Guideline for Clinical Safety Data Management: Definitions and Standards for 
Expedited Reporting (modified from ICH E2A) 
Synonyms: side effect, adverse experience. See 
also SAE, serious adverse experience. (CDISC 
glossary) 
Completed To possess every necessary or normal part or 
component or step; having come or been brought to 
a conclusion (NCI) 
Death The absence of life or state of being dead (NCI) 
Lack of efficacy The lack of expected or desired effect related to a 
therapy (NCI) 
Lost to follow-up The loss or lack of con tinuation of a subject to 
follow-up 
Non-compliance with study drug An indication that a subject has not agreed with or followed the instructions related to the study 
medication (NCI) 
Other Different than the one(s) previously specified or 
mentioned (NCI) 
Physician decision A position, opi[INVESTIGATOR_58179] a physician with reference to subject (NCI) 
Pregnancy Pregnancy is the state or condition of having a developi[INVESTIGATOR_78527] (uterus), after union of an ovum and spermatozoon, during 
the period from conception to birth. (NCI) 
Progressive disease A disease process that is increasing in extent or 
severity (NCI) 
Protocol deviation An event or decision that stands in contrast to the 
guidelines set out by [CONTACT_760] (NCI) 
Screen failure The potential subject who does not meet one or more criteria required for participation in a trial 

 
 
Approval Date :  
 05-Dec-2018 
Protocol 1883-301-013       
AGN-190584 
67 
 
CDISC Submission Value CDISC Definition 
Site terminated by [CONTACT_78588] a clinical study was stopped at a 
particular site by [CONTACT_23662] (NCI) 
Study terminated by [CONTACT_78588] a clinical study was stopped by [CONTACT_23662] (NCI) 
Withdrawal by [CONTACT_78589] a study participant has removed itself from the study (NCI) 
 

 
 
Approval Date :  
 05-Dec-2018 
Protocol 1883-301-013       
AGN-190584 
68 
 
10.5. Appendix 5: Study Tabular Summary 
Parameter Group Parameter Value 
Trial information Trial Title A Phase 3, Multicenter, Double-Masked, 
Randomized, Vehicle-Controlled, Parallel-
Group Study Evaluating the Safety and Efficacy of AGN-190584  in Participants 
with Presby[CONTACT_631927], Inc. 
 Trial Phase Classification Phase 3 Trial 
 Trial Indication Presby[CONTACT_631928] 30 days plus up to 30-day screening period 
 Planned Country of Investigational Sites [LOCATION_002] 
 Planned Number of Participants 300 
 FDA-Regulated Device Study No 
 FDA-Regulated Drug Study Yes 
 Pediatric Study No 
Participant 
information Diagnosis Group Presby[CONTACT_631929] 40 
 Planned Maximum Age of Participants 55 
 Sex of Participants Male or female 
 Stable Disease Minimum Duration Not specified 

 
 
Approval Date :  
 05-Dec-2018 
Protocol 1883-301-013       
AGN-190584 
69 
 
Parameter Group Parameter Value 
Treatments Investigational Therapy or Treatment AGN-190584 (Pi[INVESTIGATOR_143569] 1.25% 
Ophthalmic Solution) 
 Intervention Type Drug 
 Pharmacological Class of Invest. Therapy Cholinergic agonist 
 Dose per Administration 1 bilaterally 
 Dose Units Drop 
 Dosing Frequency Once daily 
 Route of Administration Topi[INVESTIGATOR_631905]-190584 Vehicle 
Trial design Study Type Interventional 
 Intervention Model Parallel 
 Planned Number of Arms 2 
 Trial is Randomized Yes 
 Randomization Quotient 1:1 
 Trial Blinding Schema Double-masked 
 Stratification Factors Age (2 groups: ≤ 50 years and > 50 years); 
baseline binocular DCNVA (2 groups: 
20/40 to 20/60 inclusively, and worse than 20/60); iris color (brown and non-brown), 
and emmetropes/non-emmetropes 
 Adaptive Design No 
 Study Stop Rules None 
 
 

 
 
Approval Date :  
 05-Dec-2018 
Protocol 1883-301-013       
AGN-190584 
70 
 
10.6. Appendix 6: Contraceptive Guidan ce and Collection of Pregnancy 
Information  
Definitions: 
WOCBP 
A woman is considered fertile following mena rche and until becoming postmenopausal unless 
permanently sterile (see below). 
Women in the following categories are not considered WOCBP: 
1. Premenarchal 
2. Premenopausal female with 1 of the following: 
• Documented hysterectomy 
• Documented bilateral salpi[INVESTIGATOR_1656] 
• Documented bilateral oophorectomy 
Note: Documentation can come from the site  personnel’s: review of the participant’s 
medical records, medical examination, or medical history interview. 
3. Postmenopausal female 
• A postmenopausal state is defined as no mens es for 12 months without an alternative 
medical cause. A high FSH level in the postmenopausal range may be used to confirm a 
postmenopausal state in women not using hormo nal contraception or HRT. However, in 
the absence of 12 months of amenorrhea, a single FSH measurement is insufficient.  
• Females on HRT and whose menopausal status is in doubt will be required to use one of 
the nonestrogen hormonal highly effective contraception methods if they wish to continue their HRT during the study. Otherwis e, they must discontinue HRT to allow 
confirmation of postmenopausal st atus before study enrollment. 
Contraception Guidance: 
Female Participants 
Female participants of childbearing potential are eligible to participate if they agree to use a 
highly effective method of contraception cons istently and correctly as described in Table 10–1 . 

 
 
Approval Date :  
 05-Dec-2018 
Protocol 1883-301-013       
AGN-190584 
71 
 

 
 
Approval Date :  
 05-Dec-2018 
Protocol 1883-301-013       
AGN-190584 
72 
 

 
 
Approval Date :  
 05-Dec-2018 
Protocol 1883-301-013       
AGN-190584 
73 
 

 
 
Approval Date :  
 05-Dec-2018 
Protocol 1883-301-013       
AGN-190584 
74 
 

 
 
Approval Date :  
 05-Dec-2018 
Protocol 1883-301-013       
AGN-190584 
75 
 

 
 
Approval Date :  
 05-Dec-2018 
Protocol 1883-301-013       
AGN-190584 
76 
 

 
 
Approval Date :  
 05-Dec-2018 
Protocol 1883-301-013       
AGN-190584 
77 
 

 
 
Approval Date :  
 05-Dec-2018 
Protocol 1883-301-013       
AGN-190584 
78 
 

 
 
Approval Date :  
 05-Dec-2018 
Protocol 1883-301-013       
AGN-190584 
79 
 

 
 
Approval Date :  
 05-Dec-2018 
Protocol 1883-301-013       
AGN-190584 
80 
 

 
 
Approval Date :  
 05-Dec-2018 
Protocol 1883-301-013       
AGN-190584 
81 
 

 
 
Approval Date :  
 05-Dec-2018 
Protocol 1883-301-013       
AGN-190584 
82 
 

 
 
Approval Date :  
 05-Dec-2018 
Protocol 1883-301-013       
AGN-190584 
83 
 

 
 
Approval Date :  
 05-Dec-2018 
Protocol 1883-301-013       
AGN-190584 
84 
 

 
 
Approval Date :  
 05-Dec-2018 
Protocol 1883-301-013       
AGN-190584 
85 
 

 
 
Approval Date :  
 05-Dec-2018 
Protocol 1883-301-013       
AGN-190584 
86 
 

 
 
Approval Date :  
 05-Dec-2018 
Protocol 1883-301-013       
AGN-190584 
87 
 

 
 
Approval Date :  
 05-Dec-2018 
Protocol 1883-301-013       
AGN-190584 
88 
 

 
 
Approval Date :  
 05-Dec-2018 
AGN-19
10.8. 
0584 
Appen d
Descrip
dix 8: Pati e
tions, an d
ent Repo r
d Instructi
89 
rted Outc o
ons 
omes Que s
Proto c
stionnaire
col 1883-30 1
s, 
 
1-013       

 
 
A p pr o v al D at e :  
 0 5- D e c- 2 0 1 8  
A G N- 1 9 0 5 8 4 
9 0 Pr ot o ccol 1 8 8 3- 3 0 11- 0 1 3       
 
 
A p pr o v al D at e :  
 0 5- D e c- 2 0 1 8  
A G N- 1 9 0 5 8 4 
9 1 Pr ot o ccol 1 8 8 3- 3 0 11- 0 1 3       
 
 
A p pr o v al D at e :  
 0 5- D e c- 2 0 1 8  
A G N- 1 9 0 5 8 4 
9 2 Pr ot o ccol 1 8 8 3- 3 0 11- 0 1 3       
 
 
Approval Date :  
 05-Dec-2018 
AGN-19
 0584 
93 
Proto c
col 1883-30 1
1-013       

 
 
Approval Date :  
 05-Dec-2018 
AGN-19
 0584 
94 
Proto c
col 1883-30 1
1-013       

 
 
Approval Date :  
 05-Dec-2018 
AGN-19
 0584 
95 
Proto c
col 1883-30 1
1-013       

 
 
Approval Date :  
 05-Dec-2018 
AGN-19
 0584 
96 
Proto c
col 1883-30 1
1-013       

 
 
A p pr o v al D at e :  
 0 5- D e c- 2 0 1 8  
A G N- 1 9 0 5 8 4 
9 7 Pr ot o ccol 1 8 8 3- 3 0 11- 0 1 3       
 
 
A p pr o v al D at e :  
 0 5- D e c- 2 0 1 8  
A G N- 1 9 0 5 8 4 
9 8 Pr ot o ccol 1 8 8 3- 3 0 11- 0 1 3       
 
 
Approval Date :  
 05-Dec-2018 
AGN-19
 0584 
99 
Proto c
col 1883-30 1
1-013       

 
 
A p pr o v al D at e :  
 0 5- D e c- 2 0 1 8  
A G N- 1 9 0 5 8 4 
1 0 0 Pr ot o ccol 1 8 8 3- 3 0 11- 0 1 3       
 
 
A p pr o v al D at e :  
 0 5- D e c- 2 0 1 8  
A G N- 1 9 0 5 8 4 
1 0 1 Pr ot o ccol 1 8 8 3- 3 0 11- 0 1 3       
 
 
Approval Date :  
 05-Dec-2018 
AGN-19
 0584 
102 
Proto c
col 1883-30 1
1-013       

 
 
A p pr o v al D at e :  
 0 5- D e c- 2 0 1 8  
A G N- 1 9 0 5 8 4 
1 0 3 Pr ot o ccol 1 8 8 3- 3 0 11- 0 1 3       
 
 
A p pr o v al D at e :  
 0 5- D e c- 2 0 1 8  
A G N- 1 9 0 5 8 4 
1 0 4 Pr ot o ccol 1 8 8 3- 3 0 11- 0 1 3       
 
 
Approval Date :  
 05-Dec-2018 
Protocol 1883-301-013       
AGN-190584 
105 
10.8.2. Near Vision Presby[CONTACT_143611]-based Questionnaire 
Near Vision Presby[CONTACT_143611] -based Questionnaire (NVPTQ) 
Instructions: This questionnaire includes 12 questions on four reading tasks that you are about 
to complete.  
 You will be asked to read text from the following examples: 
• Paragraph from a book 
• Newspaper article 
• Menu 
• Nutrition label 
 

 
 
Approval Date :  
 05-Dec-2018 
Protocol 1883-301-013       
AGN-190584 
106 

 
 
Approval Date :  
 05-Dec-2018 
Protocol 1883-301-013       
AGN-190584 
107 

 
 
Approval Date :  
 05-Dec-2018 
Protocol 1883-301-013       
AGN-190584 
108 

 
 
Approval Date :  
 05-Dec-2018 
Protocol 1883-301-013       
AGN-190584 
109 

 
 
Approval Date :  
 05-Dec-2018 
Protocol 1883-301-013       
AGN-190584 
110 

 
 
Approval Date :  
 05-Dec-2018 
Protocol 1883-301-013       
AGN-190584 
111 

 
 
Approval Date :  
 05-Dec-2018 
Protocol 1883-301-013       
AGN-190584 
112 

 
 
Approval Date :  
 05-Dec-2018 
Protocol 1883-301-013       
AGN-190584 
113 

 
 
Approval Date :  
 05-Dec-2018 
Protocol 1883-301-013       
AGN-190584 
114 

 
 
Approval Date :  
 05-Dec-2018 
Protocol 1883-301-013       
AGN-190584 
115 

 
 
Approval Date :  
 05-Dec-2018 
Protocol 1883-301-013       
AGN-190584 
116 

 
 
Approval Date :  
 05-Dec-2018 
Protocol 1883-301-013       
AGN-190584 
117 

 
 
Approval Date :  
 05-Dec-2018 
Protocol 1883-301-013       
AGN-190584 
118 

 
 
Approval Date :  
 05-Dec-2018 
Protocol 1883-301-013       
AGN-190584 
119 

 
 
Approval Date :  
 05-Dec-2018 
Protocol 1883-301-013       
AGN-190584 
120 

 
 
Approval Date :  
 05-Dec-2018 
Protocol 1883-301-013       
AGN-190584 
121 

 
 
Approval Date :  
 05-Dec-2018 
Protocol 1883-301-013       
AGN-190584 
122 

 
 
Approval Date :  
 05-Dec-2018 
Protocol 1883-301-013       
AGN-190584 
123 

 
 
Approval Date :  
 05-Dec-2018 
Protocol 1883-301-013       
AGN-190584 
124 

 
 
Approval Date :  
 05-Dec-[ADDRESS_843410] 
Surg. 2012;38(5):858-865. 
Holden BA, Fricke TR, Ho SM, Wong R, Schlen ther G, Cronjé S, et al. Global vision 
impairment due to uncorrected presb yopia. Arch Ophthalmol. 2008;126:1731-1739. 
Johnson L, Buckley JG, Scally AJ, Elliott DB. Mu ltifocal spectacles increase variability in toe 
clearance and risk of trippi[INVESTIGATOR_631906]. Invest O phthalmol Vis Sci. 2007;48:1466-1471. 
Lord SR, Dayhew J, Howland A. Multifocal glasse s impair edge-contrast sensitivity and depth 
perception and increase the risk of falls in older people. J Am Geriatr Soc. 2002;50:1760-1766. 
Moshirfar M, Desautels JD, Wallace RT, Koen N, Hoopes PC. Comparison of FDA safety and 
efficacy data for KAMRA and Raindrop corneal inlays. Int J Ophthalmol. 
2017;10(9):1446-1451. 
Pi[INVESTIGATOR_143573] 1% , 2%, and 4%. Package Insert. Fort Worth, 
TX: Alcon Laboratories, Inc. 2011. Ruiz LA, Cepeda LM, Fuentes VC. Intrastromal correction of presby[CONTACT_631930] a femtosecond 
laser system. J Refract Surg. 2009;25(10):847-854. 
Tomita M. Advances in Implantation Over the Years. Changes in technique have a direct 
correlation with decreases in a corneal inlay’s removal rate. Cataract Refract Surg Today. 
2015;June:67-68. 
Tsai JC, Forbes M. Medical Management of  Glaucoma. 3rd ed. West Islip, [LOCATION_001]: 
Professional Communications, Inc.;2009. 
Tucker J, Charman WN. The depth-of-focus of the human eye for Snellen letters. Am J Optom 
Physiol Opt. 1975;52(1):3–21. 

 
 
Approval Date :  
 05-Dec-2018ALLERGAN  
 
 
 
 
    
 
Date (DD/MMM/YYYY)/Time (PT)  Signed by:  [CONTACT_13310]  
               
                         
                         
                         
                  
                         
                         
                         
                         
                         
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
 1883-301-013 Protocol Amendment 1
05-Dec-2018 10:58 GMT-080 Clinical Development Approval
